Atea Pharmaceuticals (AVIR -0.86%), a biopharmaceutical company focused on developing therapies for viral diseases, reported its second quarter 2025 results on August 7, 2025. The release highlighted improving cost controls and continued advancement in its Phase 3 clinical program for hepatitis C, but also underscored ongoing risks from late-stage competition and a lack of near-term revenue. The company reported a GAAP net loss per share of $0.44 for Q2 2025, better than both the consensus estimate of a GAA ...

Atea Pharmaceuticals (AVIR) Q2 2025 Earnings Call August 07, 2025 04:30 PM ET Speaker0Good afternoon, and welcome to the Atea Pharmaceuticals Second Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Janae Barnes, Senior Vice President, Investor Relations and Corporate Communications. Please go ahead.Speaker1Great. Thank you, and good afternoon, everyone, and welcome to A ...